Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 8 March 2002:
Vol. 295. no. 5561, p. 1795
DOI: 10.1126/science.295.5561.1795a
Prev | Table of Contents | Next

Editors' Choice: Highlights of the recent literature

Developing small molecule drugs starts with selection of the target macromolecule, such as a cell surface receptor, and screening of candidate compounds that either block or mimic the effect of the naturally occurring ligand. Fang et al. have adapted microprinting techniques to fabricate microarrays of G protein-coupled receptors (one of the largest family of receptors), deposited from vesicular suspensions onto silane-derivatized glass slides. These membrane proteins were displayed in a structurally intact fashion as demonstrated by binding of the b-adrenergic receptor ligand CGP 12177 to both b1 and b2 receptor subtypes and not to the a2A subtype; furthermore, the b2-selective antagonist ICI 118551 preferentially diminished the b2 signal. -- GJC

J. Am. Chem. Soc., 10.1021/ja017346+ (2002).

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)